Medicare and Medicaid

Cell Therapeutics, Inc. to Pay United States $10.5 Million to Resolve Claims for Illegal Marketing of Cancer Drug

Published in Food and Drug Law Weekly, May 4th, 2007

Cell Therapeutics Inc. (CTI) of Seattle, Wash., has agreed to pay the United States $10.5 million to resolve allegations of the company's illegal marketing of the anti-cancer prescription drug Trisenox, the Justice Department announced. According to the government's complaint, CTI promoted the drug for various uses that were unapproved by the Food & Drug Administration (FDA).

The alleged "off-label" uses caused doctors to prescribe Trisenox to treat various forms of cancer for which the drug was neither approved by the FDA nor proven to be either safe or effective. The government's suit alleged that because of the company's actions, physicians who prescribed Trisenox...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2007-05-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry